News About: Pharm. Industry
Product restructuring to sweep pharmaceutical firms
Influenced by the government’s plan to slash the price of about half the drugs on the market by an average of 14 percent, a growing number of pharmaceutical firms are scrambled to go through product restructuring star...
Gilead Science Korea names new executives in shake-up
In an effort to bolster its localization efforts, Gilead Science Korea said Thursday that it has appointed two new executive directors – Chung Yeon-sim, head of the Regulatory and Market Access Team and Ban Joon-woo, ...
Assembly-private panel discussion gains no fruit
Lawmakers of the National Assembly’s Health and Welfare Committee and four law and patent experts held a public hearing on Monday over the impacts that its free trade deals with the U.S. would cause in domestic pharma...
Pharmaceutical SMEs struggle for survival
Experts are now raising concerns that the looming collapse of domestic pharmaceutical firms might in the long run lead to a de-industrialization of the country’s pharmaceutical industry, which faces cutthroat competit...
Sanofi-Pasteur redistributes hepatitis A vaccine
Sanofi-Pasteur says it has redistribute Avaxim (inactivated hepatitis A) vaccine 80U in pediatrics of 1-15 years and adolescents, which has been in short supply from 2009.
The vaccine contained in a 0.5 mL pre-fill...
Pharmaceutical firms vow to defy government’s drug pricing reform
Asserting that the government’s “ill-conceived” plan, which was announced Monday, would shake the pharmaceutical industry to its roots, Korea Pharmaceutical Manufacturers Association (KPMA) pledged joint efforts to bl...
Multinational firms calls for review of massive drug price cut plan
The Korean Research based Pharmaceutical Industry Association (KRPIA) announced Tuesday that the government’s plan to cut drug prices by an average of 14 percent starting next year should be reviewed again among relat...
Restructuring to sweep pharmaceutical industry
Fierce competition in domestic drug market is making it harder for companies to do business.
Analysts expect a large number of drugs to be expelled from the market among companies, and restructuring seems inevitabl...
Corporate revenues up, profitability down
The third quarter report card for leading pharmaceutical companies is coming out, but despite of overall revenue hike, they saw their third-quarter operating profits worsen sharply, buffeted by higher costs and heavy ...
May KORUS FTA give benefis to pharmaceutical industry?
The ruling Grand National Party (GNP) is set to ratify the long-pending Korea-U.S. free trade agreement (KORUS FTA) soon as the ational Assembly is locked in an impasse with the ruling and the opposition parties showi...
